Q4 2017 EPS Estimates for Shire PLC (SHPG) Raised by Analyst
Shire PLC (NASDAQ:SHPG) – Research analysts at William Blair lifted their Q4 2017 earnings estimates for Shire PLC in a note issued to investors on Monday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings per share of $3.76 for the quarter, up from their previous estimate of $3.75.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/20/q4-2017-eps-estimates-for-shire-plc-shpg-raised-by-analyst.html.
Other analysts have also issued research reports about the company. Royal Bank Of Canada set a $213.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Friday, August 4th. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. BTIG Research reiterated a “buy” rating and set a $242.00 target price on shares of Shire PLC in a report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 target price on shares of Shire PLC in a report on Wednesday, July 12th. Finally, ValuEngine upgraded Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $219.25.
Shire PLC (SHPG) traded down 1.61% during midday trading on Thursday, hitting $145.44. The stock had a trading volume of 763,344 shares. The firm has a market cap of $43.32 billion, a P/E ratio of 65.07 and a beta of 1.63. Shire PLC has a 52 week low of $139.36 and a 52 week high of $192.64. The stock has a 50-day moving average of $154.09 and a 200-day moving average of $164.39.
Several hedge funds have recently modified their holdings of SHPG. Hartford Financial Management Inc. boosted its holdings in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares in the last quarter. YorkBridge Wealth Partners LLC lifted its stake in shares of Shire PLC by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the last quarter. Pacer Advisors Inc. bought a new position in shares of Shire PLC in the 2nd quarter valued at $171,000. Tower Research Capital LLC TRC lifted its stake in shares of Shire PLC by 45.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 350 shares during the last quarter. Finally, Iberiabank Corp bought a new position in shares of Shire PLC in the 2nd quarter valued at $203,000. 19.24% of the stock is currently owned by hedge funds and other institutional investors.
The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio is presently 41.07%.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.